tradingkey.logo

Alkermes Plc

ALKS
查看詳細走勢圖
29.920USD
+0.550+1.87%
收盤 03/26, 16:00美東報價延遲15分鐘
2.91B總市值
20.39本益比TTM

Alkermes Plc

29.920
+0.550+1.87%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.87%

5天

+5.35%

1月

-2.64%

6月

+7.28%

今年開始到現在

+6.93%

1年

-11.19%

查看詳細走勢圖

TradingKey Alkermes Plc股票評分

單位: USD 更新時間: 2026-03-26

操作建議

Alkermes Plc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名2/391位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為43.53。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Alkermes Plc評分

相關信息

行業排名
2 / 391
全市場排名
27 / 4546
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看好

Alkermes Plc亮點

亮點風險
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
估值高估
公司最新PE估值20.39,處於3年歷史高位
機構減倉
最新機構持股175.23M股,環比減少0.01%
HACAX持倉
明星投資者HACAX持倉,最新持倉286.00股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.31

分析師目標

基於 18 分析師
買入
評級
43.529
目標均價
+53.27%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Alkermes Plc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Alkermes Plc簡介

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
公司代碼ALKS
公司Alkermes Plc
CEOPops (Richard F)
網址https://www.alkermes.com/
KeyAI